Intuitive Surgical crushed expectations.
The maker of robotic surgical systems posted adjusted earnings of $2.40 per share. Analysts expected $1.98. That's a $0.42 beat.
Revenue jumped 23% to $2.51 billion, also topping estimates.
The stock responded accordingly, surging more than 14% Wednesday. That's significant - it pushed shares back into positive territory for the year for the first time in months.
Hospitals are using more robotic surgery systems.
Intuitive makes two main products: • Da Vinci systems: Minimally invasive surgical robots • Ion systems: Robotic bronchoscopy for lung procedures
Worldwide procedures using da Vinci increased 19%. Ion procedures surged 52%.
The company also placed more systems. Da Vinci placements rose 13%. Ion placements actually declined 14%, but procedure volume on existing Ion systems more than made up for it.
Intuitive said revenue growth came from three sources: • Higher procedure volume • More system placements • Growing installed base of machines
Management is feeling confident.
Intuitive raised its full-year outlook:
Procedure growth: Now expects 17% to 17.5%, up from previous guidance of 15.5% to 17%
Gross profit margin: Now targeting 67.0% to 67.5%, up from earlier forecast of 66.0% to 67.0%
Those margin improvements are important. They show the company isn't just growing revenue - it's doing so profitably.
Robotic surgery is becoming mainstream.
William Blair analysts wrote that Intuitive "remains in the driver's seat of a market converting to robotics." They rate the stock "outperform."
The trend makes sense. Robotic systems allow surgeons to perform complex procedures with: • Greater precision • Smaller incisions • Faster patient recovery times • Reduced complications
As hospitals adopt these systems, they create recurring revenue for Intuitive. Every procedure generates income from instruments and accessories.
Intuitive's model is similar to razors and blades.
They sell or lease the robotic systems (razors). Then hospitals buy instruments and accessories for each procedure (blades).
As the installed base of systems grows, so does recurring revenue from procedures. That's why procedure volume growth of 19% is so important.
Even when system placements slow down, existing systems keep generating revenue through procedures.
Intuitive Surgical's results show the robotic surgery market is accelerating.
The 14% stock jump reflects investor enthusiasm about: • Strong earnings beat • Raised guidance • Accelerating procedure volumes • Margin expansion
The stock being back in the green for the year is significant. It had been struggling earlier in 2025 along with many healthcare stocks.
For investors, Intuitive represents exposure to a long-term healthcare trend. Surgery is gradually converting from traditional methods to robotic assistance.
The company dominates the market. Competition exists, but Intuitive has the installed base, surgeon training programs, and proven track record.
Risks remain. Hospitals face budget constraints. Capital equipment spending can slow during economic uncertainty. And competition could eventually eat into market share.
But Wednesday's results show demand is strong right now. Hospitals are buying systems and using them more frequently.
The 52% growth in Ion procedures is particularly notable. That's a newer product line showing rapid adoption in lung procedures.
With raised guidance and strong momentum, Intuitive looks positioned for continued growth. The robotic surgery conversion story is playing out as bulls hoped.
